CSI Market
Sign In | Register

Engene Therapeutics Inc (ENGN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ENGN Annual Cash Flow →
This page allows investors to follow Engene Therapeutics Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Apr 30 2026)
6 Months 		(Jan 31 2026) (Oct 31 2025) (Jul 31 2025) (Apr 30 2025)
Operating Activities
Income-59.98
Depreciation & amortization0.37
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.15
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation6.95
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.53
Non Cash Interest Expense0.32
Gain Loss On Extinguishment Of Convertible Debentures-
Change In Fair Value Of Convertible Debenture Embedded Derivative Liabilities-
Change In Fair Value Of Convertible Debentures-
Debt Issuance Costs Expensed Upon Issuance Of Convertible Debentures Recorded Using The Fair Value Option-
Non Cash Lease Expenses0.49
Net Amortization Of Premiums Accretion Of Discounts On Marketable Securities-
Increase Decrease In Operating Lease Liability-0.24
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-4.90
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities1.90
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-4.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.98
Discontinued operations0.00
Net Cash flow from Operating Activities-59.40
Investing Activities
Capital Expenditures-0.25
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities116.99
Payments to Acquire Marketable Securities-219.40
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-102.66
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.55
Long-term debt - borrowings25.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-9.17
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock23.25
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Trust Account In Connection With Reverse Recapitalization-
Payment Of Transaction Costs In Connection With The Reverse Recapitalization And Pipe Financing-
Payment Of Issuance Costs Associated With Convertible Debentures-
Repayments Of Term Loan Principal-23.05
Payments Of Issuance Costs Associated With The Pipe Financing-
Payment Of Issuance Costs Associated With Convertible Debt-
Payment Of Reverse Recapitalization And Pipe Financing Costs-
Proceeds From Public Offering126.25
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities141.73
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-59.65
Total Cash Flow-20.33
4 historic quarters locked

Sign in to unlock the full Engene Therapeutics Inc cash flow history.

Sign In Create Free Account

About Engene Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-270386

Figures are derived from filed reports and may be restated. Historical data is subject to revision.